Canaccord raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model to reflect their new 2027 estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
- Koru Medical names Eric Schiller CTO
- REPRO-MED Systems Signs New Manufacturing Agreement
- Repro-Med Systems’ Earnings Call Highlights Growth and Challenges
- Koru Medical price target raised to $6.25 from $6 at Craig-Hallum
- Strong Revenue Growth and Strategic Positioning Drive Buy Rating for REPRO-MED Systems